Spero Therapeutics Reports Q1 2025 Results and Updates

Spero Therapeutics ( (SPRO) ) has released its Q1 earnings. Here is a breakdown of the information Spero Therapeutics presented to its investors.

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multi-drug resistant bacterial infections.

In its latest earnings report, Spero Therapeutics highlighted the progress of its Phase 3 PIVOT-PO clinical trial for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections. The company also announced a new leadership appointment with Esther Rajavelu taking on the role of President and CEO.

The company’s financial results for the first quarter of 2025 showed a net loss of $13.9 million, slightly higher than the $12.7 million loss in the same period last year. Total revenue decreased to $5.9 million from $9.3 million in the previous year, primarily due to a reduction in grant revenue. However, research and development expenses decreased, reflecting lower spending on the SPR720 program, while general and administrative expenses increased due to higher personnel and consulting costs.

Spero’s cash position remains strong, with $48.9 million in cash and cash equivalents as of March 31, 2025. The company expects its existing financial resources, along with upcoming milestone payments from GSK, to support operations into the second quarter of 2026.

Looking ahead, Spero Therapeutics remains focused on advancing its clinical programs, particularly the tebipenem HBr trial, which could offer significant benefits for patients with complicated urinary tract infections. The company’s management is optimistic about its strategic direction and financial stability, positioning it well for future developments.